Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,323 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No medication Clear all
Recruiting No phase listed Observational

Effectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients

NCT06378359
View directory record Official record
Conditions
Staphylococcus Aureus Colonization, Surgical Site Infections, Healthcare Associated Infections
Interventions
Screening and decolonization for SA carriers with the 3 drug bundle, No screening for SA, no screening, Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening., Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 15, 2026, 11:34 PM EDT
Recruiting No phase listed Observational

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

NCT05539196
View directory record Official record
Conditions
Movement Disorders, Neurology, Parkinsons Disease
Interventions
Exablate Pallidotomy, Unilateral
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Quadratus Lumborum Block Versus Control for Total Hip Arthroplasty

NCT03408483
View directory record Official record
Conditions
Total Hip Arthroplasty
Interventions
Quadratus Lumborum Block (QLB), Standard of Care
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 1 Interventional

A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes

NCT00401583
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
GW786034 (pazopanib), Probe drugs
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women

NCT01749566
View directory record Official record
Conditions
HIV
Interventions
maraviroc
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 15, 2026, 11:34 PM EDT
Recruiting No phase listed Observational

A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

NCT07556159
View directory record Official record
Conditions
Asthma
Interventions
Procedure: Investigational Procedures
Other
Lead sponsor
Sanofi
Industry
Eligibility
6 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
63
States / cities
Bessemer, Alabama • Chandler, Arizona • Mesa, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

NCT03600883
View directory record Official record
Conditions
KRAS p.G12C Mutant Advanced Solid Tumors
Interventions
sotorasib, Anti PD-1/L1, Midazolam
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
39
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Intravenous Methadone Versus Intrathecal Morphine for Analgesia Following Cesarean Delivery

NCT06826742
View directory record Official record
Conditions
Cesarean Delivery
Interventions
Intravenous line (IV) Methadone, Intrathecal Morphine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib

NCT05868356
View directory record Official record
Conditions
Healthy Adults
Interventions
Treatment A, Treatment B
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 15, 2026, 11:34 PM EDT
Terminated Phase 4 Interventional

Renal Effects of Intrarenal Nesiritide

NCT00270829
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
nesiritide
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder

NCT00864123
View directory record Official record
Conditions
Obsessive-compulsive Disorder
Interventions
Cognitive-behavioral therapy, D-cycloserine, Placebo pill
Behavioral · Drug
Lead sponsor
University of South Florida
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Youth Substance Use Prevention/Reduction Through Science-based Drug Abuse Education

NCT00612482
View directory record Official record
Conditions
Substance Abuse
Interventions
drug prevention curriculum
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
14 Years to 19 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 15, 2026, 11:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Prenatal Exercise and Glucose Regulation

NCT07802262
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Gestational Diabetes Mellitus in Pregnancy, Insulin Resistance
Interventions
Acute exercises sessions with different exercise types and intensities
Behavioral
Lead sponsor
University of Central Arkansas
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Conway, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 15, 2026, 11:34 PM EDT
Completed No phase listed Observational Results available

Spinal Manipulation Services vs. Prescription Drug Therapy for Long-term Care

NCT03669354
View directory record Official record
Conditions
Low Back Pain
Interventions
Not listed
Lead sponsor
Southern California University of Health Sciences
Other
Eligibility
64 Years to 84 Years
Enrollment
195 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Whittier, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 15, 2026, 11:34 PM EDT
Recruiting Phase 3 Interventional

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 11:34 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Results available

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

NCT04357730
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
Interventions
Alteplase 50 MG [Activase]
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
La Jolla, California • Aurora, Colorado • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin D Supplementation and Effects on Mood in Emergency Medicine Residents

NCT03739671
View directory record Official record
Conditions
Seasonal Mood Disorder
Interventions
Vitamin D, No Vitamin D
Dietary Supplement
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

NCT00001832
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
gp100:209-217 (210M), Montanide ISA-51, IL-2, MART-1:26-35(27L), Abl cells, Fludarabine, Cyclophosphamide, GCSF (Growth colony stimulating factor), Apheresis
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 4 Interventional

Irritable Bowel Syndrome Evaluation and Treatment in Primary Care

NCT01641341
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Bifidobacterium infantis, Pancrelipase, Nitazoxanide, Placebo
Drug
Lead sponsor
American Academy of Family Physicians
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Lomita, California • Leawood, Kansas • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 15, 2026, 11:34 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Bone Mass Accrual in Adolescent Athletes

NCT00827151
View directory record Official record
Conditions
Amenorrhea, Bone Loss
Interventions
Estrogen
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 21 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 1 Interventional Results available

Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

NCT01318902
View directory record Official record
Conditions
Light-Chain Amyloidosis
Interventions
Ixazomib, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea

NCT00823901
View directory record Official record
Conditions
Rosacea
Interventions
Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel, Placebo gel
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 15, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection

NCT03022981
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Years to 17 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 15, 2026, 11:34 PM EDT